Jan 14 (Reuters) - Mesoblast Ltd MSB.AX :
* TO SUBMIT A ROLLING BIOLOGICS LICENSE APPLICATION WITH FDA FOR USE OF REMESTEMCEL-L IN TREATING AGVHD IN CHILDREN IN EARLY 2019
Jan 14 (Reuters) - Mesoblast Ltd MSB.AX :
* TO SUBMIT A ROLLING BIOLOGICS LICENSE APPLICATION WITH FDA FOR USE OF REMESTEMCEL-L IN TREATING AGVHD IN CHILDREN IN EARLY 2019